SCHEMBL6799314

SCHEMBL6799314

COc1ccc(C(C(=O)O)n2cncc(NC(=O)c3ccccc3)c2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
F10 P00742 1/20 0.47
PKM P14618 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC2 Q92769 2/20 0.43
SNCA P37840 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805321 0.89 IDO1 (0.47) RAB9ANPC1SMN1; SMN2TP53ALDH1A1
SCHEMBL6805808 0.88 SMN1; SMN2 (0.47) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL6803679 0.86 RAB9A (0.50) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL6803439 0.86 ALDH1A1 (0.47) RAB9ANPC1SMN1; SMN2KDM4EPKM
SCHEMBL6805622 0.86 IDO1 (0.43) SMN1; SMN2TP53ALDH1A1MEN1POLB
SCHEMBL6802997 0.86 RAB9A (0.47) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL6801198 0.85 SMN1; SMN2 (0.48) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL6805628 0.85 MEN1 (0.48) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL6805410 0.84 MAPT (0.46) RAB9ANPC1SMN1; SMN2TP53KDM4E
SCHEMBL6803978 0.82 KMT2A (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS RAB9A 2244/4885NPC1 1638/4885SMN1; SMN2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.